"Designing Growth Strategies is in our DNA"

Hemostasis and Tissue Sealing Devices Market Size, Share & Industry Analysis, By Product Type, By Application, By Technology, By Material, By End User, and Regional Forecast, 2026–2034

Last Updated: November 17, 2026 | Format: PDF | Report ID: FBI119727

 

Hemostasis and Tissue Sealing Devices Market Size and Future Outlook

Play Audio Listen to Audio Version

The hemostasis and tissue sealing devices market size was valued at USD 8.33 billion in 2025. The market is projected to grow from USD 8.89 billion in 2026 to USD 15.04 billion by 2034, exhibiting a CAGR of 6.8% during the forecast period.

Hemostasis and tissue sealing devices are surgical products designed to control bleeding, promote clot formation, seal tissue surfaces, and support vessel closure during open and minimally invasive procedures. The market includes passive topical hemostats, active hemostatic matrices, fibrin sealants, surgical patches, and energy-based vessel and tissue sealing systems used across general, cardiovascular, orthopedic, gynecologic, urologic, and other surgical specialties. The market growth is supported by increasing surgical procedure volumes, rising adoption of minimally invasive surgery, growing demand for effective intraoperative bleeding management, technological advancements in vessel sealing systems, and expanding utilization of biologic and synthetic tissue sealants across hospitals and ambulatory surgical centers.

  • For instance, in April 2025, Baxter launched a room-temperature version of Hemopatch Sealing Hemostat in Europe, enabling improved operating-room accessibility for surgeons requiring rapid hemostasis and tissue sealing during surgery.

Furthermore, Johnson & Johnson, Medtronic, Baxter International Inc., BD, and Olympus Corporation are among the prominent companies operating in the market.

Growing Adoption of Advanced Energy-Based Vessel Sealing Technologies Reshapes Market Development

A major market trend is the increasing transition from conventional mechanical hemostasis toward advanced energy-based vessel and tissue sealing technologies. Modern surgical energy platforms combine precise cutting, coagulation, vessel sealing, and tissue dissection capabilities within integrated handheld systems, helping improve surgical workflow during both open and laparoscopic procedures. Moreover, hybrid ultrasonic and bipolar technologies are increasingly being adopted across general, gynecologic, thoracic, and vascular surgeries as they allow surgeons to perform multiple tissue-management functions using fewer instruments.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Surgical Procedure Volumes and Increasing Demand for Effective Bleeding Control to Drive Market Growth

The increasing number of surgical procedures performed worldwide is a major driver of hemostasis and tissue sealing devices market growth. Nearly all complex surgical procedures require reliable bleeding management through topical hemostats, biologic sealants, or vessel sealing technologies to improve intraoperative efficiency and surgical precision. Growth in general surgery, cardiovascular procedures, orthopedic reconstruction, gynecologic surgery, and minimally invasive interventions is expanding the utilization of advanced hemostatic products across healthcare facilities. In addition, increasing adoption of laparoscopic and robotic-assisted procedures is supporting demand for compact and multifunctional vessel sealing technologies.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Overall Impact CAGR Contribution, 2026–2034 Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Rising Volume of Surgical Procedures Worldwide High 1.9% High High High
2 Increasing Adoption of Minimally Invasive Surgical Procedures High 1.6% High High High
3 Growing Adoption of Energy-Based Vessel & Tissue Sealing Technologies High 1.4% Medium High High
4 Increasing Demand for Advanced Hemostatic Agents and Tissue Sealants Medium 1.1% Medium High High
5 Expansion of Ambulatory Surgical Centers and Outpatient Procedures Medium 0.8% Medium High High
6 Others Low 0.4% Low Low Medium
Total Positive Growth Contribution 7.20%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET RESTRAINTS

High Cost of Advanced Powered & Energy Devices and Reprocessing Requirements May Limit Adoption

Advanced fibrin sealants, biologic hemostatic matrices, and energy-based vessel sealing systems generally involve higher procurement costs than conventional mechanical hemostatic techniques. Moreover, hospitals must also consider the cost of compatible generators, disposable instruments, biologic components, storage requirements, and specialized surgical accessories. In addition, reimbursement variability across countries can influence the adoption of premium biologic and energy-based products.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Overall Impact CAGR Contribution, 2026–2034
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 High Cost of Advanced Hemostatic Products and Energy-Based Sealing Systems High -0.16% High Medium Medium
2 Stringent Regulatory and Safety Requirements for Hemostatic and Biologic Products Medium -0.11% High Medium Medium
3 Availability of Conventional and Lower-Cost Bleeding Control Techniques Medium -0.08% Medium Medium Low
4 Others Low -0.05% Low Low Low
Total Negative Restraint Contribution -0.40%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Expansion of Minimally Invasive and Ambulatory Surgical Procedures to Create Significant Growth Opportunities

The continued expansion of minimally invasive surgery and ambulatory surgical centers is creating strong opportunities for manufacturers of advanced hemostatic and tissue sealing technologies. In addition, modern surgical workflows increasingly prioritize efficient bleeding control, reduced instrument exchanges, shorter procedure times, and improved tissue handling. Energy-based vessel sealing devices, absorbable hemostatic matrices, and ready-to-use sealants are increasingly integrated into outpatient and minimally invasive surgical procedures.

MARKET CHALLENGES

Maintaining Clinical Performance Across Different Tissue Types and Surgical Specialties Remains a Major Challenge

Hemostasis and tissue sealing devices must deliver consistent clinical performance across highly variable tissue characteristics, bleeding severity, surgical approaches, and anatomical locations. Manufacturers face ongoing challenges related to balancing sealing strength, thermal spread, biocompatibility, absorption time, ease of handling, and surgeon usability. Moreover, biologic products must also meet stringent safety and manufacturing standards, while energy-based devices require precise control of thermal energy to minimize unintended tissue injury. Innovation is therefore focused on improving reliability, ease of application, and compatibility across multiple surgical specialties.

Segmentation Analysis

By Product Type

Increasing Adoption of Advanced Vessel Sealing Technologies to Drive Energy-Based Vessel & Tissue Sealers Segment Growth

Based on product type, the market is segmented into passive topical hemostats, active hemostatic matrices, fibrin sealants & patches, energy-based vessel & tissue sealers, and others.

The energy-based vessel & tissue sealers segment held the highest share of the global market in 2025. The segment growth is attributed to increasing adoption of minimally invasive surgeries and growing demand for effective bleeding control. These devices help surgeons seal vessels, coagulate tissue, and perform controlled tissue cutting during surgical procedures. Furthermore, their growing utilization across general, gynecologic, cardiovascular, and other surgeries is supporting segment growth.

The fibrin sealants & patches segment is projected to register the highest CAGR of 6.7% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Rising General and Abdominal Surgical Procedures to Drive Segment Growth

Based on application, the market is segmented into general & abdominal surgery, cardiovascular & vascular surgery, orthopedic & spine surgery, gynecologic & urologic surgery, and others.

The general & abdominal surgery segment held the highest hemostasis and tissue sealing devices market share in 2025. The growth of this segment is attributed to high number of gastrointestinal, colorectal, hepatobiliary, hernia, and other abdominal surgical procedures. These procedures frequently require effective bleeding control, tissue sealing, and vessel management during surgery. In addition, an increasing adoption of laparoscopic procedures is further increasing the utilization of energy-based vessel sealers and topical hemostatic products. Furthermore, expanding access to surgical treatment is expected to support segment growth.

The orthopedic & spine surgery segment is expected to grow at the highest CAGR of 6.7% during the forecast period.

By Technology

Growing Preference for Energy-Based Tissue Management to Drive Segment Growth

Based on technology, the market is segmented into passive matrix hemostasis, thrombin-activated hemostasis, fibrin polymerization, energy-mediated tissue fusion, and others.

The energy-mediated tissue fusion segment held the highest market share in 2025. This is attributed to increasing adoption of advanced surgical energy systems for vessel sealing, coagulation, tissue fusion, and cutting. These technologies allow surgeons to perform multiple functions with a single device and help reduce the need for frequent instrument changes. Furthermore, increasing preference for precise and efficient tissue management is contributing to segment growth.

The fibrin polymerization segment is expected to grow at the considerable CAGR of 6.8% during the forecast period.

By Material

Increasing Adoption of Advanced Synthetic Materials to Drive Segment Growth

Based on material, the market is segmented into human-derived, animal-derived, plant/cellulose-derived, synthetic/polymeric, and others.

The synthetic/polymeric segment held the highest market share in 2025. This growth is attributed to the increasing adoption of advanced synthetic materials for effective tissue sealing and bleeding control during surgical procedures. Also, these materials offer consistent performance, controlled absorption, and strong tissue-sealing properties, supporting their use across different surgical applications. Furthermore, continued development of biocompatible polymers and growing demand for advanced alternatives to biologically derived materials are expected to support segment growth.

The human-derived segment is expected to grow at the considerable CAGR of 6.6% during the forecast period.

By End User

High Volume of Complex Surgical Procedures to Drive Hospitals Segment Growth

Based on end user, the market is segmented into hospitals, ambulatory surgical centers, specialty orthopedic centers, and others.

The hospitals segment held the dominant market position in 2025. The segment growth is attributed to the high number of complex and major surgical procedures performed in these facilities. Hospitals have advanced operating rooms, specialized surgical teams, emergency services, intensive care, and postoperative monitoring facilities required for complex procedures. They also perform cardiovascular, abdominal, orthopedic, oncology, and other surgeries requiring effective bleeding management.

The ambulatory surgical centers segment is expected to register the substantial CAGR of 8.4% during the forecast period.

Hemostasis and Tissue Sealing Devices Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

North America Hemostasis and Tissue Sealing Devices Market Size, 2025 (USD Billion)

To get more information on the regional analysis of this market, Download Free sample

North America held a dominant share in 2024, valuing at USD 3.05 billion, and also maintained the leading share in 2025, with USD 3.26 billion. The growth of the regional market is attributed to its advanced healthcare infrastructure, high volume of surgical procedures, and widespread adoption of minimally invasive surgery. Strong utilization of biologic hemostatic products and advanced surgical energy systems further supports regional demand. The presence of established medical device companies and strong adoption of new surgical technologies also contribute to market growth.

U.S. Hemostasis and Tissue Sealing Devices Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 3.17 billion in 2026, accounting for roughly 35.6% of global sales.

Europe

Europe is projected to record a considerable growth rate of 5.9% over the forecast period, and reach a valuation of USD 2.36 billion by 2026. Growth is supported by established surgical healthcare systems, increasing adoption of advanced biologic sealants, expanding minimally invasive procedures, and continued innovation across tissue sealing technologies.

U.K. Hemostasis and Tissue Sealing Devices Market

The U.K. market in 2026 is estimated at around USD 0.40 billion, representing roughly 4.5% of global hemostasis and tissue sealing devices revenues.

Germany Hemostasis and Tissue Sealing Devices Market

Germany’s market is projected to reach approximately USD 0.54 billion in 2026, equivalent to around 6.1% of global hemostasis and tissue sealing devices sales.

Asia Pacific

Asia Pacific is estimated to held considerable share in the global market and reach USD 2.24 billion in 2026. Rapid healthcare infrastructure development, increasing surgical procedure volumes, rising healthcare expenditure, expansion of tertiary hospitals, and growing adoption of advanced minimally invasive surgery are driving strong regional growth.

Japan Hemostasis and Tissue Sealing Devices Market

The Japanese market in 2026 is estimated at around USD 0.43 billion, accounting for roughly 4.9% of global hemostasis and tissue sealing devices revenues.

China Hemostasis and Tissue Sealing Devices Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 0.76 billion, representing roughly 8.6% of global hemostasis and tissue sealing devices sales.

India Hemostasis and Tissue Sealing Devices Market

The Indian market in 2026 is estimated at around USD 0.31 billion, accounting for roughly 3.5% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 0.46 billion in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 0.17 billion in 2026.

South Africa Hemostasis and Tissue Sealing Devices Market

The South Africa market is projected to reach around USD 0.09 billion in 2026, representing roughly 1.0% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Product Innovation and Advanced Surgical Hemostasis Technologies to Intensify Market Competition

The hemostasis and tissue sealing devices market has a semi-consolidated competitive structure, comprising prominent players such as Johnson & Johnson, Medtronic, Baxter International Inc., BD, and Olympus Corporation. Major companies increasingly focus on ergonomic design, multifunctionality, reduced instrument exchanges, energy efficiency, precision tissue handling, and compatibility with minimally invasive procedures.

  • For instance, in March 2025, Johnson & Johnson MedTech launched the DUALTO Energy System, an integrated surgical energy platform supporting monopolar, bipolar, ultrasonic, and advanced bipolar instruments across open and minimally invasive surgery.

Other notable players in the global market B. Braun SE, Applied Medical Resources Corporation, Erbe Elektromedizin GmbH, Teleflex Incorporated, and Corza Medical, Inc. These companies are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY HEMOSTASIS AND TISSUE SEALING DEVICES COMPANIES PROFILED

  • Johnson & Johnson (U.S.)
  • Medtronic plc (Ireland)
  • Baxter International Inc. (U.S.)
  • BD (U.S.)
  • Olympus Corporation (Japan)
  • Braun SE (Germany)
  • Applied Medical Resources Corporation (U.S.)
  • Erbe Elektromedizin GmbH (Germany)
  • Teleflex Incorporated (U.S.)
  • Corza Medical, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

  • August 2026: Hangzhou AGS MedTech received U.S. FDA 510(k) clearance for its Hemoclip (511 and 543 series), classified as a hemostatic metal clip for the gastrointestinal tract.
  • August 2026: 3-D Matrix received U.S. FDA 510(k) clearance for PuraStat GI, a hemostatic device intended for endoscopic gastrointestinal use.
  • June 2026: Wilson-Cook Medical received U.S. FDA 510(k) clearance for the Hemospray Endoscopic Hemostat (HEMO-[X]), expanding regulatory activity in endoscopic hemostasis.
  • April 2026: Lifescience Plus received U.S. FDA 510(k) clearance for BloodSTOP iX Trauma Matrix, a hemostatic wound dressing without thrombin or other biologics.
  • February 2026: Speciality Fibres and Materials received U.S. FDA 510(k) clearance for its Ganymede and Ganymede-X hemostatic wound dressing portfolio.

REPORT COVERAGE

The hemostasis and tissue sealing devices market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 6.8% from 2026-2034
Unit Value (USD Billion)
Segmentation By Product Type, Application, Technology, Material, End User, and Region
By Product Type
  • Passive Topical Hemostats
  • Active Hemostatic Matrices
  • Fibrin Sealants & Patches
  • Energy-Based Vessel & Tissue Sealers
  • Others
By Application
  • General & Abdominal Surgery
  • Cardiovascular & Vascular Surgery
  • Orthopedic & Spine Surgery
  • Gynecologic & Urologic Surgery
  • Others
By Technology
  • Passive Matrix Hemostasis
  • Thrombin-Activated Hemostasis
  • Fibrin Polymerization
  • Energy-Mediated Tissue Fusion
  • Others
By Material
  • Human-Derived
  • Animal-Derived
  • Plant/Cellulose-Derived
  • Synthetic/Polymeric
  • Others
By End User 
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Orthopedic Centers
  • Others
By Region 
  • North America (By Product Type, Application, Technology, Material, End User, and Country)
    • U.S. 
      • By Product Type
    • Canada
      • By Product Type
  • Europe (By Product Type, Application, Technology, Material, End User, and Country/Sub-region)
    • Germany 
      • By Product Type
    • U.K.
      • By Product Type
    • France 
      • By Product Type
    • Spain 
      • By Product Type
    • Italy 
      • By Product Type
    • Scandinavia 
      • By Product Type
    • Rest of Europe
      • By Product Type
  • Asia Pacific (By Product Type, Application, Technology, Material, End User, and Country/Sub-region)
    • China 
      • By Product Type
    • Japan 
      • By Product Type
    • India 
      • By Product Type
    • Australia 
      • By Product Type
    • Southeast Asia 
      • By Product Type
    • Rest of Asia Pacific 
      • By Product Type
  • Latin America (By Product Type, Application, Technology, Material, End User, and Country/Sub-region)
    • Brazil
      • By Product Type
    • Mexico
      • By Product Type
    • Rest of Latin America
      • By Product Type
  • Middle East & Africa (By Product Type, Application, Technology, Material, End User, and Country/Sub-region)
    • GCC
      • By Product Type
    • South Africa
      • By Product Type
    • Rest of Middle East & Africa
      • By Product Type

Research Methodology

1. Bottom Up Approaches

Approach 1: Country-Level Surgical Procedure and Hemostasis Utilization Analysis

  • Estimate country-level surgical procedure volumes across general, cardiovascular, orthopedic, gynecologic, urologic, and other surgical specialties.
  • Assess utilization of topical hemostats, fibrin sealants, active matrices, and vessel sealing devices per procedure.
  • Determine hemostasis device penetration according to surgical complexity and bleeding management requirements.
  • Calculate market value using: Eligible Surgical Procedures×Hemostasis Device Penetration×Average Selling Price
  • Aggregate country-level estimates into regional and global market values.

Approach 2: Product Volume, Technology Mix and ASP Analysis

  • Estimate annual demand across passive hemostats, active matrices, fibrin sealants, vessel sealers, and specialty products.
  • Assess technology adoption across passive matrix, thrombin activation, fibrin polymerization, and energy-mediated tissue fusion.
  • Estimate reusable versus disposable product utilization.
  • Validate average selling prices using manufacturer catalogs, distributor pricing, hospital procurement, and tender databases.
  • Cross-check calculated market values against supplier revenue and hospital purchasing data.

Approach 3: Hospital and Ambulatory Surgical Center Demand Analysis

  • Identify hospitals, ambulatory surgical centers, specialty orthopedic centers, and other surgical facilities.
  • Estimate annual surgical throughput and hemostatic product consumption by facility type.
  • Evaluate purchasing patterns across biologic sealants, topical hemostats, and energy-based vessel sealing systems.
  • Validate installed base of compatible surgical energy platforms.
  • Aggregate facility-level demand into country and regional estimates.

2. Top Down Approaches

Approach 1: Manufacturer Revenue & Product Portfolio Analysis

  • Identify major manufacturers operating in surgical hemostasis and tissue sealing.
  • Review annual reports, investor presentations, regulatory filings, product catalogs, and official company disclosures.
  • Estimate revenue attributable specifically to hemostatic and tissue sealing products.
  • Allocate revenues across product type, application, technology, end user, and geography.
  • Exclude unrelated surgical instruments, implants, diagnostic devices, and non-hemostatic capital equipment.
  • Compare manufacturer-derived estimates with bottom-up market calculations.

Approach 2: Triangulation, Validation & Forecast Modeling

  • Compare manufacturer revenues with country-level surgical demand.
  • Validate procedure volumes through hospital databases and healthcare statistics.
  • Cross-check technology penetration using regulatory approvals and clinical adoption.
  • Assess regional growth through healthcare infrastructure, minimally invasive surgery adoption, and ambulatory surgery expansion.
  • Forecast individual country markets before aggregating regional and global totals.
  • Apply conservative, base-case, and higher-growth forecasting scenarios.
  • Report all market values in USD billion rounded to two decimal places while maintaining underlying dataset precision for CAGR calculations.

3. List of Key Sources

  • Company annual reports
  • SEC filings
  • Investor presentations
  • Official company product catalogs
  • Product brochures
  • Instructions for Use
  • U.S. Food and Drug Administration
  • FDA 510(k) Premarket Notification Database
  • European Medical Device Regulation
  • EUDAMED
  • WHO
  • OECD
  • World Bank
  • National healthcare agencies
  • Hospital discharge databases
  • National surgical procedure databases
  • Surgical specialty associations
  • American College of Surgeons
  • Society of American Gastrointestinal and Endoscopic Surgeons
  • Orthopedic surgery associations
  • Cardiovascular surgery associations
  • Gynecology and urology societies
  • PubMed
  • ClinicalTrials.gov
  • Peer-reviewed surgical journals
  • Distributor catalogs
  • Government procurement databases
  • Hospital procurement records
  • Official company press releases

4. Primary Interviews

Supply Side Interviews: 60%

  • Key respondents: Hemostatic product manufacturers, fibrin sealant companies, surgical energy device manufacturers, vessel sealing technology suppliers, biologic material suppliers, collagen matrix manufacturers, distributors, product managers, R&D executives, regulatory professionals, sales directors, and business development managers.

Demand Side Interviews: 40%

  • Key Respondents: General surgeons, cardiovascular surgeons, orthopedic surgeons, spine surgeons, gynecologists, urologists, laparoscopic surgeons, operating-room managers, hospital procurement teams, ambulatory surgical center administrators, biomedical engineers, and sterile processing professionals.


Frequently Asked Questions

According to Fortune Business Insights, the global market value stood at USD 8.33 billion in 2025 and is projected to reach USD 15.04 billion by 2034.

In 2025, the North America market value stood at USD 3.26 billion.

The market is expected to exhibit a CAGR of 6.8% during the forecast period of 2026-2034.

By product type, the energy-based vessel & tissue sealers segment is expected to hold highest share in the market.

Rising surgical procedure volumes and increasing demand for effective bleeding control to drive market growth.

Johnson & Johnson, Medtronic, Baxter International Inc., BD, and Olympus Corporation are the major players in the global market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 200
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann